Day One Biopharmaceuticals Inc. (DAWN) stock is soaring 5.04% in pre-market trading on Monday, following the announcement of new data from its OJEMDA™ (tovorafenib) trial in pediatric low-grade glioma (pLGG) to be presented at the upcoming Society for Neuro-Oncology (SNO) Annual Meeting.

The company revealed that updated results from the registrational Phase 2 FIREFLY-1 trial will be presented in an oral session at the SNO meeting, scheduled for November 19-23, 2025. The trial evaluates tovorafenib as a once-weekly oral monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG with a known activating BRAF alteration. The presentation will showcase more than 36 months of follow-up data, demonstrating durable responses and clinical stability off treatment, as well as newly disclosed treatment-free interval data.

Investors are reacting positively to this news, as the extended follow-up data and treatment-free interval information could potentially strengthen OJEMDA's position in the pediatric brain cancer treatment landscape. The presentation by Dr. Cassie Klein from the Children's Hospital of Pennsylvania on November 23, 2025, is highly anticipated and could provide further insights into the drug's efficacy and long-term benefits for young patients with this challenging form of brain cancer.